Analytical Data
-
Gene name
TNFRSF13B
-
简介
TNFRSF13B protein is a receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS and exhibits high-affinity binding to both ligands. Its activation stimulates B-cell and T-cell function and modulates humoral immunity through calcineurin-dependent NF-AT activation as well as NF-kappa-B and AP-1 activation. TNFRSF13B Protein, Human (R119A, R122A, HEK293, Fc) is the recombinant human-derived TNFRSF13B protein, expressed by HEK293 , with C-hFc labeled tag and R119A, R122A, , , mutation.
- Application
-
Alternative Names
CD267; TACI; TNFRSF13B
-
Species
Human
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14836-1
-
Expression Region
S2-T166, R119A, R122A
-
Molecular Weight
50-60 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TNFRSF13B, also known as TACI (Transmembrane Activator and CAML Interactor), is a member of the tumor necrosis factor receptor superfamily that plays a crucial role in the immune system. It is primarily expressed on B cells and is involved in regulating humoral immunity, including the activation and differentiation of B cells. Research has shown that mutations in TNFRSF13B are associated with eliciting immune deficiencies, particularly common variable immunodeficiency (CVID), leading to increased susceptibility to infections and autoimmune diseases. Given its pivotal role in immune regulation, the production of recombinant TNFRSF13B protein has garnered significant interest for both therapeutic and research purposes. Studying this recombinant protein can provide insights into its functional mechanisms, interactions with other immune molecules, and its role in B cell receptor signaling pathways. Moreover, understanding TNFRSF13B's structure-function relationship aids in developing potential immunotherapies to modulate immune responses in various pathological conditions. As researchers explore the potential of TNFRSF13B as a biomarker for immune-related disorders, the recombinant protein serves as a valuable tool for drug development and functional assays, ultimately advancing our understanding of immune system dynamics and improving therapeutic strategies for related diseases.
